VANCOUVER – Today the Canadian Institutes of Health Research (CIHR) is announcing it will match funding from BRI Biopharmaceutical Research Inc (BRI) for a total of $750,000 over a three year Industry Partnered Collaborative Research Grant. This money will enable ongoing research collaborations between Dr. Yuzhuo Wang’s laboratories at the BC Cancer Agency and Vancouver Prostate Centre (VPC), and BRI to develop new state-of-the-art experimental cancer models.Read the press release here (91 kb PDF, opens in new window) Dr. Wang, Dr.
The Michael Smith Foundation for Health Research (MSFHR) and the Vancouver Coastal Research Institute are pleased to present a lecture by one of British Columbia’s most innovative scientists — a man who has bridged the gap between clinical research and new commercial treatments for disease. Dr. Martin Gleave is the most recent recipient of the MSFHR Aubrey J.
Dr. Kim Chi is one of two recipients of the BC Cancer Agency Clinician Researcher Award, funded by BC Cancer Foundation donors.Selected by their peers from a high calibre of applicants, Dr. Chi and Dr. David W. Scott were awarded a cumulative $1.5 million over five years. Dr. Chi's project will focus on translational research in prostate cancer, while Dr. Scott will further investigate treatment failure in B cell lymphoid cancers.
The groundbreaking computer-aided drug design work of Dr. Artem Cherkasov is featured in MONTECRISTO, Vancouver's quarterly lifestyle magazine. See the article here.
Dr. Martin Gleave, chief executive officer of PC-TRiADD, is the winner of the fourth annual Aubrey J. Tingle Prize. Created in honour of the Michael Smith Foundation for Health Research's founding president and CEO, this award is given to a British Columbia researcher whose work in health research is internationally recognized and has significant impact on advancing clinical or health services and policy research.“Martin has contributed significantly to the understanding and treatment of prostate cancer, a disease that affects thousands of Canadian men every year,” says Dr.
The Vancouver Prostate Centre's PC-TRiADD program has recieved an additional award of $11.3 million for 2013 - 2018. Please read our press release here (PDF). A link to the Centres of Excellence for Commercialization and Research story is here.
Many men survive prostate cancer, but thousands of others — whose cancer spreads — inevitably develop resistance to even the most promising treatments, leaving them with few medical options and a dwindling span of life. Now, armed with a new $10 million grant, a multi-centre “dream team’’ of scientists is embarking on a groundbreaking undertaking into personalized medicine. The goal: to overcome therapeutic resistance in the disease and revolutionize treatment for patients with advanced prostate cancer.
Drs. Martin Gleave and Colin Collins part of new pan-Canadian prostate cancer networkA new pan-Canadian network of prostate cancer researchers formed by the Terry Fox Research Institute (TFRI) aims to address this need with approximately $4-million provided by the Terry Fox Foundation and the Canadian Partnership Against Cancer. The funding was announced today at the CHUM Research Centre (CRCHUM).
Vancouver Prostate Centre is proud to partner with Step Into Action to raise awareness of the critical role of early detection, and to raise funds for prostate cancer research.Dr. Riley Senft completed his cross-Canada run from Cape Spear to Vancouver as a personal quest to save the lives of future prostate cancer patients by educating men on the steps to early prostate cancer detection.
Focusing on early detection and disease preventionOver 150 clinicians, scientists, and staff will be pioneering new treatments and cures and working on disease prevention strategies in the new Robert H.N Ho Research Centre. The facility, adjacent to the Jack Bell Research Centre, is home to three internationally-recognized health research programs: the Centre for Hip Health and Mobility; the Ovarian Cancer Research Program, and an expansion of the Vancouver Prostate Centre.